{"id":4521,"date":"2020-06-19T15:21:16","date_gmt":"2020-06-19T19:21:16","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/"},"modified":"2024-12-03T14:56:55","modified_gmt":"2024-12-03T19:56:55","slug":"randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/","title":{"rendered":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease"},"content":{"rendered":"<h2 class=\"title\">Abstract<\/h2>\n<div id=\"en-abstract\" class=\"abstract-content selected\">\n<p><strong class=\"sub-title\">Objective:\u00a0<\/strong>To investigate the efficacy and safety of nabilone for agitation in patients with moderate-to-severe Alzheimer&rsquo;s disease (AD).<\/p>\n<p><strong class=\"sub-title\">Design:\u00a0<\/strong>This 14-week randomized double-blind crossover trial compared nabilone to placebo (6 weeks each) with a 1-week washout between phases.<\/p>\n<p><strong class=\"sub-title\">Setting:\u00a0<\/strong>Patients were recruited from a long-term care facility and geriatric psychiatry clinics.<\/p>\n<p><strong class=\"sub-title\">Participants:\u00a0<\/strong>Patients had AD (standardized Mini-Mental State Examination [sMMSE \u226424]) and agitation (Neuropsychiatric Inventory-Nursing Home version [NPI-NH]-agitation\/aggression subscore \u22653).<\/p>\n<p><strong class=\"sub-title\">Intervention:\u00a0<\/strong>Nabilone (target 1-2 mg) versus placebo.<\/p>\n<p><strong class=\"sub-title\">Measurements:\u00a0<\/strong>The primary outcome was agitation (Cohen Mansfield Agitation Inventory [CMAI]). Secondary outcomes included NPI-NH total, NPI-NH caregiver distress, cognition (sMMSE and Severe Impairment Battery [SIB] or Alzheimer&rsquo;s Disease Assessment Scale of Cognition), global impression (Clinician&rsquo;s Global Impression of Change [CGIC]), and adverse events.<\/p>\n<p><strong class=\"sub-title\">Results:\u00a0<\/strong>Thirty-nine patients (mean \u00b1 SD age = 87 \u00b1 10, sMMSE = 6.5 \u00b1 6.8, CMAI = 67.9 \u00b1 17.6, NPI-NH total = 34.3 \u00b1 15.8, 77% male, nabilone dose = 1.6 \u00b1 0.5 mg) were randomized. There were no crossover or treatment-order effects. Using a linear mixed model, treatment differences (95% CI) in CMAI (b = -4.0 [-6.5 to -1.5], t(30.2) = -3.3, p = 0.003), NPI-NH total (b = -4.6 [-7.5 to -1.6], t(32.9) = -3.1, p = 0.004), NPI-NH caregiver distress (b = -1.7 [-3.4 to -0.07, t(33.7) = -2.1, p = 0.041), and sMMSE (b = 1.1 [0.1-2.0], t(22.6) = 2.4, p = 0.026) all favored nabilone. However, in those who completed the SIB (n = 25) treatment differences favored placebo (b = -4.6 [-7.3 to -1.8], t(20.7) = -4.8, p = 0.003). CGIC improvement during nabilone (47%) and placebo (23%) was not significantly different (McNemar&rsquo;s test, exact p = 0.09). There was more sedation during nabilone (45%) compared to placebo (16%) phases (McNemar&rsquo;s test, exact p = 0.02), but treatment-limiting sedation was not significantly different (McNemar&rsquo;s test, exact p = 0.22).<\/p>\n<p><strong class=\"sub-title\">Conclusions:\u00a0<\/strong>Nabilone may be an effective treatment for agitation. However, sedation and cognition should be closely monitored.<\/p>\n<\/div>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4521","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Objective:\u00a0To investigate the efficacy and safety of nabilone for ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/\",\"name\":\"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2020-06-19T19:21:16+00:00\",\"dateModified\":\"2024-12-03T19:56:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV","og_description":"Abstract Objective:\u00a0To investigate the efficacy and safety of nabilone for ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:56:55+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/","name":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2020-06-19T19:21:16+00:00","dateModified":"2024-12-03T19:56:55+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/randomized-placebo-controlled-trial-of-nabilone-for-agitation-in-alzheimers-disease-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4521"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}